News

Stimulating Interactions

NEWS

Ethan Perlstein featured in Science Careers

Ethan Perlstein featured in Science Careers Ethan Perlstein never planned to be a CEO. Ever since his college research internship in a lab at the National Institutes of Health (NIH), he had dreamed of becoming a professor at a high-powered research institution. After completing his Ph.D. in molecular and cellular biology at Harvard and earning a Lewis-Sigler fellowship at Princeton, […]

Read more

Privail Wins the Vator Splash Health 2015 People’s Choice Award

At Vator Splash Health, Privail won the People’s Choice Award. Here’s the video of Anwaar Al-Zireeni, Privail co-founder and CEO, giving on of the winning presentation. Privail is developing point-of-care diagnostics for the early detection of infectious diseases, with an initial focus on HIV. Unlike current diagnostic methods, Privail’s test detects the virus itself and is available in a simple, […]

Read more

Encoded Genomics, Xcell Bio among those to benefit from Illumina Accelerator’s $40M

Illumina today announced that its startup accelerator has secured $40 million from Viking Global Investors to fund promising genomic firms. Accelerator graduates that raise between $1 million and $5 million in new capital will receive additional dollar-for-dollar match funding from Illumina Accelerator Boost Capital. Read more at GenomeWeb

Read more

Neopeutics Wins 2015 North America Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as […]

Read more

Symic Adds Expertise to its Board

Symic Biomedical announced today the appointment of Barbara Yanni and William J. Newell to its board of directors. Mr. Newell is the CEO of Sutro Biopharma, Inc. which has entered into a strategic collaboration and acquisition option with Celgene regarding their therapeutic technology platform. Ms. Yanni retired in 2014 from Merck & Co., Inc. where she was most recently Vice […]

Read more

Amarantus to Present Positive Alzheimer’s Disease Biomarker Data

Amarantus announced that its abstract titled “The LymPro® Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively Intact Subjects” was accepted for poster presentation at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.  Read the press release at […]

Read more

MedGenome to Raise $15M in Second Round of Funding

MedGenome, backed by Mu Sigma co-founders Dhiraj Rajaram and Ambiga Dhiraj, is looking to raise $15 million in a second round of funding to set up additional genome test labs. The clinical research and diagnostics firm is seeking a valuation of more than $100 million, a near ten-fold jump from last year, when it raised $4 million in its first […]

Read more

Amarantus Inks Alzheimer’s Biomarker Test Deal with Anavex

Amarantus BioScience Holdings today said that it has signed a deal to provide biomarker test services to Anavex Life Sciences for studies of that firm’s Alzheimer’s drug candidate. Under the deal, Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69 in specific sub-populations of peripheral […]

Read more

Senior Management Changes at Assembly Biosciences

Co-founder Derek Small succeeds Russell H. Ellison, MD, as CEO, as had been agreed in the merger last year that established Assembly. Small remains President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. Read the press release at Globe […]

Read more

John Mulcahy, SiteOne Therapeutics

Developing a non-addictive painkiller to compete with opiates Mission Bay Capital portfolio company John Mulcahy is co-founder and vice-president of research at SiteOne Therapeutics, a company developing a non-addictive oral replacement for narcotic pain medications such as oxycodone and Vicodin. SiteOne recently won a $1.4M SBIR grant and raised $1.5M in private funding, including an investment by QB3’s fund Mission […]

Read more
Page 7 of 8« First...45678

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    14:00-15:30
    08/31/2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter